Abstract：
Currently, the main cause of cancer chemotherapy failure is multi-drug resistance (MDR), which involves a variety of complex mechanisms. Compared with traditional small-molecule chemotherapy, targeted nanomedicines offer promising alternative strategies as an emerging form of therapy, especially active targeted nanomedicines. However, although single-targeted nanomedicines have made some progress in tumor therapy, the complexity of tumor microenvironment and tumor heterogeneity limits their efficacy. Dual-targeted nanomedicines can simultaneously target two tumor-specific factors that cause tumor MDR, which have the potential in overcoming tumor MDR superior to single-targeted nanomedicines by further enhancing cell uptake and cytotoxicity in new forms, as well as the effectiveness of tumor-targeted delivery. This review discusses tumor MDR mechanisms and the latest achievements applied to dual-targeted nanomedicines in tumor MDR.
摘要：
目前,肿瘤化疗失败的主要原因是多药耐药(MDR),其中涉及各种复杂的机制。与传统的小分子化疗相比,靶向纳米药物作为一种新兴的治疗形式提供了有希望的替代策略，特别是有活性的靶向纳米药物。然而,尽管单靶向纳米药物在肿瘤治疗方面取得了一些进展，肿瘤微环境的复杂性和肿瘤异质性限制了其疗效。双靶向纳米药物可以同时靶向导致肿瘤MDR的两种肿瘤特异性因子，通过进一步增强新形式的细胞摄取和细胞毒性，具有克服肿瘤MDR优于单靶向纳米药物的潜力，以及肿瘤靶向递送的有效性。本文综述了肿瘤MDR的机制以及双靶向纳米药物在肿瘤MDR中应用的最新成果。
